Business Context and Reporting Period
Company: Biomerica, Inc. (BMRA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended May 31, 2025
Business Overview: Biomerica is a global biomedical technology company developing, manufacturing, and marketing diagnostic and therapeutic products. Key markets include clinical laboratories and point-of-care settings. The company focuses on gastrointestinal diseases, food intolerances, and inflammatory conditions, with flagship products including the inFoods® IBS diagnostic-guided therapy and the hp+detect™ test for H. pylori.
Key Financial Metrics
| Metric | Fiscal 2025 | Fiscal 2024 |
|---|---|---|
| Net Sales | $5,311,000 | $5,415,000 |
| Gross Profit | $498,000 | $611,000 |
| Gross Margin | 9.4% | 11.3% |
| Net Loss | $(4,973,000) | $(5,978,000) |
| Operating Expenses | $5,635,000 | $6,978,000 |
| Cash and Cash Equivalents (End of Period) | $2,399,000 | $4,170,000 |
| Working Capital | $3,135,000 | $5,527,000 |
| Accumulated Deficit | $(53,168,000) | $(48,195,000) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased by 2% ($104,000) primarily due to a 26% drop in over-the-counter sales and reduced clinical lab demand, partially offset by a 44% increase in contract manufacturing revenue.
- Cost Reductions: Operating expenses decreased by 19% ($1,343,000). Selling, General, and Administrative (SG&A) expenses fell 16% due to a 15% workforce reduction and lower stock compensation. Research and Development (R&D) expenses dropped 31% as the company transitioned from intensive development to commercialization.
- Margin Compression: Gross margin declined from 11.3% to 9.4% due to a shift in sales mix toward lower-margin contract manufacturing and higher costs associated with the inFoods® product.
- Capital Structure: The company executed a 1-for-8 reverse stock split effective April 21, 2025. It raised $2,015,000 in net proceeds via an At-The-Market (ATM) offering during the fiscal year.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
The independent auditor has issued a report expressing substantial doubt about the company's ability to continue as a going concern for the next twelve months. Management states that current cash and cash equivalents are insufficient to meet operating requirements for the next year without additional financing or significant revenue growth.
Outlook and Strategy
- Commercialization: Focus remains on expanding the inFoods® IBS product and hp+detect™ adoption. The company is actively pursuing insurance reimbursement for inFoods® IBS.
- Cost Management: Continued cost-cutting measures, including workforce reductions, are in place to extend the cash runway.
- Financing: The company is exploring debt or equity financing and strategic alternatives to sustain operations.
Risks and Contingencies
- Regulatory Compliance: Ongoing efforts to meet EU In Vitro Diagnostic Medical Device Regulation (IVDR) requirements, with formal applications submitted by May 26, 2025.
- Concentration Risk: One distributor accounted for 31% of net sales in 2025. Four distributors accounted for 69% of gross accounts receivable.
- International Exposure: Significant revenue exposure to Asia (32%) and Europe (24%), subject to trade tariffs, currency fluctuations, and geopolitical instability.
Subsequent Events
- Received a $1.1 million cash refund from the IRS for Employee Retention Credits (ERC) in July 2025.
- Generated an additional $919,000 in net proceeds from ATM sales in July and August 2025.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $2.4 million cash balance plus subsequent proceeds against the stated operating burn rate and the "substantial doubt" going concern qualification.
- Reimbursement Status: Confirm the progress of insurance reimbursement applications for the inFoods® IBS product, which is critical for revenue scaling.
- ATM Capacity: Review the remaining capacity under the Form S-3 shelf registration, noting the limitation based on public float (approx. $232,000 remaining as of filing date).
- Customer Concentration: Assess the stability of the top distributor relationships, given that 31% of sales and 27% of receivables are tied to single entities.
- Inventory Valuation: Review the inventory reserve of $471,000 (24% of gross inventory) and the auditor's critical audit matter regarding inventory valuation estimates.